Furthermore, preclinical studies identifying specific mutations, such as in STK11/LKB1, that reduce cancer cell sensitivity to metformin, support the rationale for using drug combinations to enhance the response of cancer cells to prolonged treatment with metformin10,11. The gene discussed is STK11; the disease is cancer.